Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Maillard M, Launay M, Royer B, Guitton J, Gautier-Veyret E, Broutin S, Tron C, Le Louedec F, Ciccolini J, Richard D, Alarcan H, Haufroid V, Tafzi N, Schmitt A, Etienne-Grimaldi MC, Narjoz C, Thomas F; Groupe de Pharmacologie Clinique Oncologique (GPCO). Maillard M, et al. Among authors: royer b. Br J Clin Pharmacol. 2023 Feb;89(2):762-772. doi: 10.1111/bcp.15536. Epub 2022 Oct 3. Br J Clin Pharmacol. 2023. PMID: 36104927 Free PMC article.
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.
Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Loriot MA, Paci A, Royer B, Thomas F, Ciccolini J. Etienne-Grimaldi MC, et al. Among authors: royer b. Semin Oncol. 2017 Apr;44(2):159-160. doi: 10.1053/j.seminoncol.2017.06.001. Epub 2017 Jul 4. Semin Oncol. 2017. PMID: 28923215 No abstract available.
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC. Loriot MA, et al. Among authors: royer b. Bull Cancer. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24. Bull Cancer. 2018. PMID: 29486921 Free article. Review. French.
Exposure-response analysis of Raltitrexed assessing liver toxicity.
Royer B, Schmitt A, Nguyen T, Paillard MJ, Jary M, Demarchi M, Vernerey D, Henriques J, Jacquin M, Borg C, Kim S. Royer B, et al. Br J Clin Pharmacol. 2021 Mar;87(3):1327-1337. doi: 10.1111/bcp.14519. Epub 2020 Sep 4. Br J Clin Pharmacol. 2021. PMID: 32789966 Free article. Clinical Trial.
Population Pharmacokinetics of Palbociclib in aReal-World Situation.
Royer B, Kaderbhaï C, Fumet JD, Hennequin A, Desmoulins I, Ladoire S, Ayati S, Mayeur D, Ilie S, Schmitt A. Royer B, et al. Pharmaceuticals (Basel). 2021 Feb 24;14(3):181. doi: 10.3390/ph14030181. Pharmaceuticals (Basel). 2021. PMID: 33668400 Free PMC article.
Pharmacokinetics and Pharmacodynamic of Alpelisib.
Royer B, Kaderbhaï CG, Schmitt A. Royer B, et al. Clin Pharmacokinet. 2023 Jan;62(1):45-53. doi: 10.1007/s40262-022-01195-2. Epub 2023 Jan 12. Clin Pharmacokinet. 2023. PMID: 36633813 Review.
281 results